Inhibition of mammary gland tumors by short-term treatment of estradiol-3-benzoate associated with down-regulation of estrogen receptor ERalpha and ERbeta.
Epidemiological evidence indicates that estrogens are one of the risk factors of breast cancer. However, there have been reports that pre-pubertal estrogen exposure is related to reduced breast cancer risk. These discrepancies made us investigate the time-point and duration of estrogen exposure. Our studies focus on the effect of estradiol-3-benzoate (EB) on the mammary gland that was exposed to carcinogens. Ninety-six female Sprague-Dawley rats were randomly divided into 6 groups. Animals at 7 weeks of age were injected with 7,12-dimethylbenz[a]anthracene (DMBA) in groups 1, 2 and 3 or N-methyl-N-nitrosourea (MNU) in groups 4, 5 and 6. One week later, the animals were subjected to sustained treatment with 0 micro g (groups 1 and 4), 30 micro g (groups 2 and 5) or 300 micro g (groups 3 and 6) of EB containing pellets for 4 weeks. All animals were sacrificed at 5 weeks or 21 weeks after carcinogen treatment, for the examination of mammary gland differentiation or mammary gland tumors, respectively. At 21 weeks after carcinogen treatment, the incidence of mammary tumors in group 2 was significantly decreased (P<0.05). EB treatment decreased the multiplicity of DMBA- or MNU-induced mammary gland tumors. At 5 weeks after carcinogen treatment, there were increased branchings of the mammary gland, and there was also a decrease of ERalpha and ERbeta in EB treatment groups. Taken together with these results, we conclude that EB has an inhibitory effect on mammary carcinogenesis, and it suggests that this inhibition may be associated with the differentiation of mammary gland and modulation of ERalpha and ERbeta.
Kang
Jin Seok
JS
National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul, Korea. kang@med.osaka-cu.ac.jp
Kim
Seyl
S
Che
Jeong-Hwan
JH
Nam
Ki Taek
KT
Kim
Dae Joong
DJ
Jang
Dong Deuk
DD
Yang
Ki-Hwa
KH
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity; D000477:Alkylating Agents / Q000633:toxicity; D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D002454:Cell Differentiation / Q000187:drug effects; D015536:Down-Regulation; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000378:metabolism*; D005260:Female; D008321:Mammary Glands, Animal / Q000254:growth & development / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008770:Methylnitrosourea / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley
D000477:Alkylating Agents; D002273:Carcinogens; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; C074283:estradiol 3-benzoate; D004958:Estradiol; D015127:9,10-Dimethyl-1,2-benzanthracene; D008770:Methylnitrosourea